Skip to main content
SpringerLink
Log in

Colorektales Karzinom – Besondere Aspekte in der Versorgung alter und geriatrischer Patienten

  • Living reference work entry
  • First Online:
Geriatrische Onkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 123 Accesses

Zusammenfassung

Das Colonkarzinom ist eine der häufigsten Krebserkrankungen weltweit. Die Neuerkrankungsrate in Deutschland liegt bei über 60,000 Menschen jährlich (Thermann und Seufferlein 2010). Zudem steigt die Zahl der Neuerkrankungen mit dem Alter. So ist auch der Darmkrebs eine Erkrankung des älteren Menschen, ca. 45 % der Patienten sind ≥75 Jahre alt (Aparicio et al. 2017). Dem gegenüber steht ein Mangel an Erkenntnis über die besonderen Erfordernisse dieser Patienten. Dies betrifft u. a. den Einsatz geriatrischer Assessments in der klinischen Versorgung, die Unterrepräsentation dieser Altersgruppe in klinischen Studien, sowie das mangelnden Verständnis spezieller altersabhängiger Veränderungen, die den klinischen Verlauf von Patienten mit colorektalem Karzinom im Alter maßgeblich beeinflussen (Extermann 2005; Dale et al. 2012). Das folgende Kapitel fasst praxisnah die aktuell vorliegende Evidenz zur Therapie des colorektalen Karzinoms älterer Patienten zusammen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Adam R, Frilling A, Elias D, Laurent C, Ramos E, Capussotti L, Poston GJ, Wicherts DA, de Haas RJ (2010) Liver resection of colorectal metastases in elderly patients. Br J Surg 97(3):366–376. https://doi.org/10.1002/bjs.6889

    Article  CAS  PubMed  Google Scholar 

  • Andre T (2017a) Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study. J Clin Oncol 35 (suppl; abstr 3531)

    Google Scholar 

  • Andre T (2017b) Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: the French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. J Clin Oncol 35 (suppl; abstr 3500)

    Google Scholar 

  • Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351. https://doi.org/10.1056/NEJMoa032709350/23/2343

    Article  CAS  PubMed  Google Scholar 

  • Aparicio T, Gargot D, Teillet L, Maillard E, Genet D, Cretin J, Locher C, Bouche O, Breysacher G, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Auby D, Faroux R, Bachet JB, Lepere C, Khemissa F, Sobhani I, Boulat O, Mitry E, Jouve JL (2017) Geriatric factors analyses from FFCD 2001–02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. Eur J Cancer 74:98–108. https://doi.org/10.1016/j.ejca.2016.09.029, [pii] S0959-8049(16)32475-3

    Article  PubMed  Google Scholar 

  • Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, Cretin J, Locher C, Bouche O, Breysacher G, Charneau J, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Mitry E (2013a) Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001–02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 31(11):1464–1470. https://doi.org/10.1200/JCO.2012.42.9894

    Article  CAS  PubMed  Google Scholar 

  • Aparicio T, Lavau-Denes S, Phelip JM, Maillard E, Jouve JL, Gargot D, Gasmi M, Locher C, Adhoute X, Michel P, Khemissa F, Lecomte T, Provencal J, Breysacher G, Legoux JL, Lepere C, Charneau J, Cretin J, Chone L, Azzedine A, Bouche O, Sobhani I, Bedenne L, Mitry E (2016) Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02). Ann Oncol 27(1):121–127. https://doi.org/10.1093/annonc/mdv491

    Article  CAS  PubMed  Google Scholar 

  • Aparicio T, Schischmanoff O, Poupardin C, Soufir N, Angelakov C, Barrat C, Levy V, Choudat L, Cucherousset J, Boubaya M, Lagorce C, Guetz GD, Wind P, Benamouzig R (2013b) Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. Dig Liver Dis 45(3):245–250. https://doi.org/10.1016/j.dld.2012.09.013, [pii] S1590-8658(12)00371-4

    Article  CAS  PubMed  Google Scholar 

  • Arai T, Kasahara I, Sawabe M, Honma N, Aida J, Tabubo K (2010) Role of methylation of the hMLH1 gene promoter in the development of gastric and colorectal carcinoma in the elderly. Geriatr Gerontol Int 10(Suppl 1):S207–S212. https://doi.org/10.1111/j.1447-0594.2010.00590.xGGI590

    Article  PubMed  Google Scholar 

  • Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–237

    Article  CAS  PubMed  Google Scholar 

  • Beppu N, Kobayashi M, Matsubara N, Noda M, Yamano T, Doi H, Kamikonya N, Kakuno A, Kimura F, Yamanaka N, Yanagi H, Tomita N (2015) Comparison of the pathological response of the mesorectal positive nodes between short-course chemoradiotherapy with delayed surgery and long-course chemoradiotherapy in patients with rectal cancer. Int J Colorectal Dis 30(10):1339–1347. https://doi.org/10.1007/s00384-015-2321-8

    Article  PubMed  Google Scholar 

  • Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S (2015) FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51(10):1243–1252. https://doi.org/10.1016/j.ejca.2015.04.007, [pii] S0959-8049(15)00311-1

    Article  CAS  PubMed  Google Scholar 

  • Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48(10):1466–1475. https://doi.org/10.1016/j.ejca.2012.02.057, [pii] S0959-8049(12)00209-2

    Article  CAS  PubMed  Google Scholar 

  • Bonner JA (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 22 (14_suppl, 5507–5507)

    Google Scholar 

  • Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28. https://doi.org/10.1016/S1470-2045(09)70311-0

    Article  CAS  PubMed  Google Scholar 

  • Bujko K, Nasierowska-Guttmejer A, Wyrwicz L, Malinowska M, Krynski J, Kosakowska E, Rutkowski A, Pietrzak L, Kepka L, Radziszewski J, Olszyna-Serementa M, Bujko M, Danek A, Kryj M, Wydmanski J, Zegarski W, Markiewicz W, Lesniak T, Zygulski I, Porzuczek-Zuziak D, Bebenek M, Maciejczyk A, Polkowski W, Czeremszynska B, Cieslak-Zeranska E, Toczko Z, Radkowski A, Kolodziejski L, Szczepkowski M, Majewski A, Jankowski M (2013) Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study. Radiother Oncol 107(2):171–177. https://doi.org/10.1016/j.radonc.2013.03.001, [pii] S0167-8140(13)00080-7

    Article  PubMed  Google Scholar 

  • Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudelko M, Kryj M, Oledzki J, Szmeja J, Sluszniak J, Serkies K, Kladny J, Pamucka M, Kukolowicz P (2004) Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 72(1):15–24. https://doi.org/10.1016/j.radonc.2003.12.006, [pii] S0167814004000040

    Article  CAS  PubMed  Google Scholar 

  • Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Krynski J, Michalski W, Oledzki J, Kusnierz J, Zajac L, Bednarczyk M, Szczepkowski M, Tarnowski W, Kosakowska E, Zwolinski J, Winiarek M, Wisniowska K, Partycki M, Beczkowska K, Polkowski W, Stylinski R, Wierzbicki R, Bury P, Jankiewicz M, Paprota K, Lewicka M, Cisel B, Skorzewska M, Mielko J, Bebenek M, Maciejczyk A, Kapturkiewicz B, Dybko A, Hajac L, Wojnar A, Lesniak T, Zygulska J, Jantner D, Chudyba E, Zegarski W, Las-Jankowska M, Jankowski M, Kolodziejski L, Radkowski A, Zelazowska-Omiotek U, Czeremszynska B, Kepka L, Kolb-Sielecki J, Toczko Z, Fedorowicz Z, Dziki A, Danek A, Nawrocki G, Sopylo R, Markiewicz W, Kedzierawski P, Wydmanski J (2016) Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 27(5):834–842. https://doi.org/10.1093/annonc/mdw062

    Article  CAS  PubMed  Google Scholar 

  • Cogdill AP, Andrews MC, Wargo JA (2017) Hallmarks of response to immune checkpoint blockade. Br J Cancer 117(1):1–7. https://doi.org/10.1038/bjc.2017.136

    Article  PubMed  PubMed Central  Google Scholar 

  • Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14(11):1077–1085. https://doi.org/10.1016/S1470-2045(13)70154-2

    Article  CAS  PubMed  Google Scholar 

  • Dale JE, Sebjornsen S, Leh S, Rosler C, Aaserud S, Moller B, Fluge O, Erichsen C, Nadipour S, Korner H, Pfeffer F, Dahl O (2017) Multimodal therapy is feasible in elderly anal cancer patients. Acta Oncol 56(1):81–87. https://doi.org/10.1080/0284186X.2016.1244356

    Article  CAS  PubMed  Google Scholar 

  • Dale W, Mohile SG, Eldadah BA, Trimble EL, Schilsky RL, Cohen HJ, Muss HB, Schmader KE, Ferrell B, Extermann M, Nayfield SG, Hurria A (2012) Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst 104(8):581–589. https://doi.org/10.1093/jnci/djs145

    Article  PubMed  PubMed Central  Google Scholar 

  • Dekker JW, Gooiker GA, Bastiaannet E, van den Broek CB, van der Geest LG, van de Velde CJ, Tollenaar RA, Liefers GJ (2014) Cause of death the first year after curative colorectal cancer surgery; a prolonged impact of the surgery in elderly colorectal cancer patients. Eur J Surg Oncol 40(11):1481–1487. https://doi.org/10.1016/j.ejso.2014.05.010, [pii] S0748-7983(14)00468-5

    Article  CAS  PubMed  Google Scholar 

  • Di Benedetto F, Berretta M, D’Amico G, Montalti R, De Ruvo N, Cautero N, Guerrini GP, Ballarin R, Spaggiari M, Tarantino G, Di Sandro S, Pecchi A, Luppi G, Gerunda GE (2011) Liver resection for colorectal metastases in older adults: a paired matched analysis. J Am Geriatr Soc 59(12):2282–2290. https://doi.org/10.1111/j.1532-5415.2011.03734.x

    Article  PubMed  Google Scholar 

  • Diaz-Nieto R, Fenwick S, Malik H, Poston G (2017) Defining the optimal use of ablation for metastatic colorectal cancer to the liver without high-level evidence. Curr Treat Options Oncol 18(2):8. https://doi.org/10.1007/s11864-017-0452-6

    Article  PubMed  Google Scholar 

  • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25(7):1346–1355. https://doi.org/10.1093/annonc/mdu141

    Article  CAS  PubMed  Google Scholar 

  • Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C, Johansson H, Machado M, Hjern F, Hallbook O, Syk I, Glimelius B, Martling A (2017) Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 18(3):336–346. https://doi.org/10.1016/S1470-2045(17)30086-4

    Article  PubMed  Google Scholar 

  • Extermann M (2005) Geriatric assessment with focus on instrument selectivity for outcomes. Cancer J 11(6):474–480

    Article  PubMed  Google Scholar 

  • Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ 3rd, Balducci L (2012) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118(13):3377–3386. https://doi.org/10.1002/cncr.26646

    Article  PubMed  Google Scholar 

  • Faiz O, Haji A, Bottle A, Clark SK, Darzi AW, Aylin P (2011) Elective colonic surgery for cancer in the elderly: an investigation into postoperative mortality in English NHS hospitals between 1996 and 2007. Colorectal Dis 13(7):779–785. https://doi.org/10.1111/j.1463-1318.2010.02290.xCDI2290

    Article  CAS  PubMed  Google Scholar 

  • Fietkau R, Rodel C, Hohenberger W, Raab R, Hess C, Liersch T, Becker H, Wittekind C, Hutter M, Hager E, Karstens J, Ewald H, Christen N, Jagoditsch M, Martus P, Sauer R (2007) Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys 67(4):1008–1019. https://doi.org/10.1016/j.ijrobp.2006.10.020, [pii] S0360-3016(06)03349-9

    Article  PubMed  Google Scholar 

  • Fietkau R, Zettl H, Klocking S, Kundt G (2004) Incidence, therapy and prognosis of colorectal cancer in different age groups. A population-based cohort study of the Rostock Cancer Registry. Strahlenther Onkol 180(8):478–487. https://doi.org/10.1007/s00066-004-1260-z

    Article  PubMed  Google Scholar 

  • Folprecht G (2010) Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer (MCRC): a pooled analysis of the crystal and opus studies. Ann Oncol 21(Suppl 8):195

    Google Scholar 

  • Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Kohne CH (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15(9):1330–1338. https://doi.org/10.1093/annonc/mdh34415/9/1330

    Article  CAS  PubMed  Google Scholar 

  • Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Kohne CH (2014) Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 25(5):1018–1025. https://doi.org/10.1093/annonc/mdu088

    Article  CAS  PubMed  Google Scholar 

  • Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Kohne CH (2008) Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26(9):1443–1451. https://doi.org/10.1200/JCO.2007.14.050926/9/1443

    Article  CAS  PubMed  Google Scholar 

  • Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318; discussion 318–321

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Francois E, Berdah JF, Chamorey E, Lesbats G, Teissier E, Codoul JF, Badetti JL, Hebert C, Mari V (2008) Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. Cancer Chemother Pharmacol 62(6):931–936. https://doi.org/10.1007/s00280-008-0681-2

    Article  CAS  PubMed  Google Scholar 

  • Frasson M, Braga M, Vignali A, Zuliani W, Di Carlo V (2008) Benefits of laparoscopic colorectal resection are more pronounced in elderly patients. Dis Colon Rectum 51(3):296–300. https://doi.org/10.1007/s10350-007-9124-0

    Article  PubMed  Google Scholar 

  • Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA (2014) Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer 14:897. https://doi.org/10.1186/1471-2407-14-897

    Article  PubMed  PubMed Central  Google Scholar 

  • Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22(10):1797–1806. https://doi.org/10.1200/JCO.2004.09.059

    Article  CAS  PubMed  Google Scholar 

  • van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, Rodriguez J, Kroning H, Wolf I, Ganju V, Walpole E, Boucher E, Tichler T, Shacham-Shmueli E, Powell A, Eliadis P, Isaacs R, Price D, Moeslein F, Taieb J, Bower G, Gebski V, Van Buskirk M, Cade DN, Thurston K, Gibbs P (2016) SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 34(15):1723–1731. https://doi.org/10.1200/JCO.2015.66.1181

    Article  PubMed  Google Scholar 

  • Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J (2013) Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 18(9):1004–1012. https://doi.org/10.1634/theoncologist.2013-0107

    Article  PubMed  PubMed Central  Google Scholar 

  • Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29(10):1261–1270. https://doi.org/10.1200/JCO.2010.30.1366

    Article  PubMed  Google Scholar 

  • Jehn CF, Boning L, Kroning H, Possinger K, Luftner D (2012) Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 106(2):274–278. https://doi.org/10.1038/bjc.2011.554

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345(9):638–646. https://doi.org/10.1056/NEJMoa010580

    Article  CAS  PubMed  Google Scholar 

  • Klautke G, Kuchenmeister U, Foitzik T, Ludwig K, Semrau S, Prall F, Klar E, Fietkau R (2007) Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. Radiother Oncol 85(3):379–384. https://doi.org/10.1016/j.radonc.2007.10.042, [pii] S0167-8140(07)00551-8

    Article  CAS  PubMed  Google Scholar 

  • Klautke G, Sauer R (2014) Neoadjuvant short-course radiotherapy followed by chemotherapy or simultaneous radiochemotherapy for local unresectable rectal cancer. Strahlenther Onkol 190(3):317–318. https://doi.org/10.1007/s00066-013-0549-1

    Article  CAS  PubMed  Google Scholar 

  • Kouloulias V, Plataniotis G, Kouvaris J, Dardoufas C, Gennatas C, Uzunoglu N, Papavasiliou C, Vlahos L (2005) Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol 28(1):91–99

    Article  PubMed  Google Scholar 

  • Kurian A, Suryadevara S, Ramaraju D, Gallagher S, Hofmann M, Kim S, Zebley M, Fassler S (2011) In-hospital and 6-month mortality rates after open elective vs open emergent colectomy in patients older than 80 years. Dis Colon Rectum 54(4):467–471. https://doi.org/10.1007/DCR.0b013e3182060904, [pii] 00003453-201104000-00012

    Article  PubMed  Google Scholar 

  • Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lorimer PD, Motz BM, Kirks RC, Boselli DM, Walsh KK, Prabhu RS, Hill JS, Salo JC (2017) Pathologic complete response rates after neoadjuvant treatment in rectal cancer: an analysis of the national cancer database. Ann Surg Oncol 24(8):2095–2103. https://doi.org/10.1245/s10434-017-5873-8

    Article  PubMed  Google Scholar 

  • Louis DJ, Hsu A, Brand MI, Saclarides TJ (2009) Morbidity and mortality in octogenarians and older undergoing major intestinal surgery. Dis Colon Rectum 52(1):59–63. https://doi.org/10.1007/DCR.0b013e31819754d4, [pii] 00003453-200901000-00010

    Article  PubMed  Google Scholar 

  • Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919. https://doi.org/10.1056/NEJMoa1414325

    Article  PubMed  Google Scholar 

  • McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O’Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ (2013) Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 31(20):2600–2606. https://doi.org/10.1200/JCO.2013.49.6638

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mitry E, Bouvier AM, Esteve J, Faivre J (2005) Improvement in colorectal cancer survival: a population-based study. Eur J Cancer 41(15):2297–2303. https://doi.org/10.1016/j.ejca.2005.01.028, [pii] S0959-8049(05)00564-2

    Article  PubMed  Google Scholar 

  • Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, Andre T (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. doi:10.1016/S1470-2045(17)30422-9

    PubMed  Google Scholar 

  • Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Kohne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J, Seymour M, Starling N, Van Cutsem E, Aapro M (2015) Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 26(3):463–476. doi:10.1093/annonc/mdu253

    Article  CAS  PubMed  Google Scholar 

  • Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17(8):2412–2418. https://doi.org/10.1200/JCO.1999.17.8.2412

    Article  CAS  PubMed  Google Scholar 

  • Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heussner P, Hohenberger W, Holstege A, Hubner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W (2013) S3-guideline colorectal cancer version 1.0. Z Gastroenterol 51(8):753–854. https://doi.org/10.1055/s-0033-1350264

    Article  CAS  PubMed  Google Scholar 

  • Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol 23(6):1531–1536. https://doi.org/10.1093/annonc/mdr488

    Article  CAS  PubMed  Google Scholar 

  • Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Van Cutsem E, Lutz MP, Nordlinger B (2012) Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23(10):2619–2626. https://doi.org/10.1093/annonc/mds053

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA (2008) Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 9(5):494–501. https://doi.org/10.1016/S1470-2045(08)70129-3

    Article  PubMed  Google Scholar 

  • Sanoff HK, Carpenter WR, Sturmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D (2012) Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 30(21):2624–2634. https://doi.org/10.1200/JCO.2011.41.1140

    Article  PubMed  PubMed Central  Google Scholar 

  • Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15):1091–1097. https://doi.org/10.1056/NEJMoa010957

    Article  CAS  PubMed  Google Scholar 

  • Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A (2007) End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25(29):4569–4574. https://doi.org/10.1200/JCO.2006.10.4323

    Article  PubMed  Google Scholar 

  • Sastre J, Aranda E, Gravalos C, Massuti B, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Diaz-Rubio E, Hidalgo M (2011) First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 77(1):78–84. https://doi.org/10.1016/j.critrevonc.2009.11.005, [pii] S1040-8428(09)00229-7

    Article  CAS  PubMed  Google Scholar 

  • Sastre J, Massuti B, Pulido G, Guillen-Ponce C, Benavides M, Manzano JL, Reboredo M, Rivera F, Gravalos C, Safont MJ, Martinez Villacampa M, Llovet P, Dotor E, Diaz-Rubio E, Aranda E (2015) First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer 51(11):1371–1380. https://doi.org/10.1016/j.ejca.2015.04.013, [pii] S0959-8049(15)00349-4

    Article  CAS  PubMed  Google Scholar 

  • Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14(12):1735–1743

    Article  CAS  PubMed  Google Scholar 

  • Schiffmann L, Klautke G, Wedermann N, Gock M, Prall F, Fietkau R, Rau B, Klar E (2013) Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy – a matched pair analysis. BMC Cancer 13:388. https://doi.org/10.1186/1471-2407-13-388

    Article  PubMed  PubMed Central  Google Scholar 

  • Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG (2015) Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol. doi:10.1200/JCO.2015.60.9107

    PubMed Central  Google Scholar 

  • Schrag D (2016) The relationship between primary tumor sidedness and prognosis in colorectal cancer. J Clin Oncol 34 (suppl; abstr 3505)

    Google Scholar 

  • Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32(21):2240–2247. https://doi.org/10.1200/JCO.2013.53.2473

    Article  CAS  PubMed  Google Scholar 

  • Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS 2): an open-label, randomised factorial trial. Lancet 377(9779):1749–1759. https://doi.org/10.1016/S0140-6736(11)60399-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508. https://doi.org/10.1016/S1470-2045(15)70127-0

    Article  CAS  PubMed  Google Scholar 

  • Takeda A, Sanuki N, Kunieda E (2014) Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol 20(15):4220–4229. https://doi.org/10.3748/wjg.v20.i15.4220

    Article  PubMed  PubMed Central  Google Scholar 

  • Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V (2016) Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2016.37972565703

    Google Scholar 

  • Thermann P, Seufferlein T (2010) Aktuelle Therapie des Kolonkarzinoms. Der Gastroenterologe 5(1):57–71. https://doi.org/10.1007/s11377-009-0387-y

    Article  Google Scholar 

  • Toh JW, de Souza P, Lim SH, Singh P, Chua W, Ng W, Spring KJ (2016) The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy. Clin Colorectal Cancer 15(4):285–291. https://doi.org/10.1016/j.clcc.2016.07.007, [pii] S1533-0028(16)30108-6

    Article  PubMed  Google Scholar 

  • Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580. https://doi.org/10.1200/JCO.2007.11.0833, [pii] 25/29/4575

    Article  PubMed  Google Scholar 

  • Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A (2012) Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 30(27):3353–3360. https://doi.org/10.1200/JCO.2012.42.5645

    Article  CAS  PubMed  Google Scholar 

  • Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Diaz-Rubio E, Gilberg F, Cassidy J (2012) Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23(5):1190–1197. https://doi.org/10.1093/annonc/mdr366

    Article  CAS  PubMed  Google Scholar 

  • Yamano T, Yamauchi S, Kimura K, Babaya A, Hamanaka M, Kobayashi M, Fukumoto M, Tsukamoto K, Noda M, Tomita N, Sugihara K (2017) Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: a retrospective multicentre study. Eur J Cancer 81:90–101. https://doi.org/10.1016/j.ejca.2017.05.024, [pii] S0959-8049(17)30979-6

    Article  PubMed  Google Scholar 

  • Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29(28):3768–3774. https://doi.org/10.1200/JCO.2011.36.4539

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • van der Zee J, Gonzalez GD (2002) The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia 18(1):1–12

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Onkologie, Heilig-Geist Hospital Bensheim, Rodensteinstr. 94, 64625, Bensheim, Deutschland

    Nicolai Härtel

  2. Klinik und Praxis für Radioonkologie, Klinikum Chemnitz, Flemmingstr. 2, 09116, Chemnitz, Deutschland

    Gunther Klautke

  3. Klinik für Gefäßchirurgie und Endovaskuläre Chirurgie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland

    Ulrich Ronellenfitsch

Authors
  1. Nicolai Härtel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gunther Klautke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulrich Ronellenfitsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolai Härtel .

Editor information

Editors and Affiliations

  1. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Matthias Ebert

  2. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Nicolai Härtel

  3. Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Thüringen, Germany

    Ulrich Wedding

Section Editor information

  1. Interdisziplinäres Tumorzentrum, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland

    Nicolai Härtel

Rights and permissions

Reprints and permissions

Copyright information

© 2017 © Springer-Verlag GmbH Deutschland

About this entry

Cite this entry

Härtel, N., Klautke, G., Ronellenfitsch, U. (2017). Colorektales Karzinom – Besondere Aspekte in der Versorgung alter und geriatrischer Patienten. In: Ebert, M., Härtel, N., Wedding, U. (eds) Geriatrische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-49083-9_29-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-49083-9_29-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-49083-9

  • Online ISBN: 978-3-662-49083-9

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation